Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-81. (Canceled)

Claim 82. (Currently Amended): A pharmaceutical composition for reducing skin pigmentation, wherein the pharmaceutical composition is an ointment, cream, lotion or emulsion formulated for percutaneous absorption by topical administration, comprising a skin pigmentation reducing effective amount of a compound that effects an alteration in late endosomal/lysosomal trafficking in a skin cell and a dermatologically acceptable dermatologically-acceptable carrier, wherein the pharmaceutical composition is an ointment, cream, lotion or emulsion formulated for percutaneous absorption by topical administration, and wherein the compound that effects the alteration in late endosomal/lysosomal trafficking is selected from the group consisting of:

Appl. No.: 09/827,428
Reply to Office Action of 05/18/06

$$CH_3$$
 CH_3 CH_3

and

and combinations thereof.

Claims 83-92. (Canceled)

Claim 93. (New): The pharmaceutical composition of claim 82, further comprising a skin-peeling agent.

Claim 94. (New): The pharmaceutical composition of claim 93, wherein the skin-peeling agent is glycolic acid or trichloroacetic acid.

Claim 95. (New): The pharmaceutical composition of claim 82, further comprising a sunscreen.

Claim 96. (New): The pharmaceutical composition of claim 95, wherein the sunscreen is a UVA blocker or a UVB blocker.

Reply to Office Action of 05/18/06

Claim 97. (New):

The pharmaceutical composition of claim 82, further comprising retinoic

acid.

Claim 98. (New):

The pharmaceutical composition of claim 82, further comprising 4-

hydroxyanisole.

Claim 99. (New):

The pharmaceutical composition of claim 82, further comprising ascorbic

acid.

Claim 100. (New):

The pharmaceutical composition of claim 82, further comprising

magnesium ascorbate.

Claim 101. (New):

The pharmaceutical composition of claim 82, further comprising an anti-

oxidant.

Claim 102. (New):

The pharmaceutical composition of claim 101, wherein the anti-oxidant is

resveratrol.

Claim 103. (New):

The pharmaceutical composition of claim 82, further comprising a

tyrosinase inhibitor.

Claim 104. (New): The pharmaceutical composition of claim 103, wherein the tyrosinase

inhibitor is selected from the group consisting of resorcinol, hydroquinone, kojic acid, and

melamine.

Claim 105. (New): The pharmaceutical composition of claim 82, further comprising an agent that enhances percutaneous administration selected from the group consisting of dimethylsulfoxide, dimethylacetamide, dimethylformamide, azone, acetone, propylene glycol, and polyethylene glycol.

Claim 106. (New): The pharmaceutical composition of claim 82, wherein the compound is a pharmaceutically-acceptable acid salt of a compound selected from the group consisting of:

$$CH_3$$
 CH_3 CH_3

and combinations thereof.

Claim 107. (New): The pharmaceutical composition of claim 82, wherein the compound is a pharmaceutically-acceptable base salt of a compound selected from the group consisting of:

$$CH_3$$
 CH_3
 CH_3

$$CH_3$$
 CH_3 CH_3

$$H_3C$$
 CH_3
 CH_3

$$CH_3$$
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3

and combinations thereof.